What are the administration instructions for Zosyn (piperacillin/tazobactam) 3.375 g intravenously, including reconstitution, dilution, infusion rate, and dosing intervals?

Administration Instructions for Zosyn 3.375 g IV

Administer Zosyn 3.375 g intravenously every 6 hours as a 30-minute infusion for most serious infections, or consider extended infusion (3-4 hours) in critically ill patients to optimize pharmacodynamic targets. 1

Standard Dosing and Administration

Dose and Frequency:

• 3.375 g (3 g piperacillin + 0.375 g tazobactam) every 6 hours is the FDA-approved standard regimen for most indications including intra-abdominal infections, skin/soft tissue infections, and community-acquired pneumonia 1
• Total daily dose: 13.5 g (12 g piperacillin + 1.5 g tazobactam)
• Treatment duration: typically 7-10 days 1

Infusion Method:

• Standard infusion: 30 minutes 1
• The drug comes pre-mixed in GALAXY containers (50 mL for 3.375 g dose) ready for administration after thawing to room temperature 1

Extended Infusion Strategy (Preferred for Critically Ill)

For severe infections, sepsis, or critically ill patients, extended infusion significantly improves outcomes:

• Administer 3.375 g over 4 hours every 8 hours (alternative to standard dosing) 2, 3
• This achieves superior pharmacodynamic targets (100% time above MIC) compared to 30-minute infusions 3, 4
• In one study of critically ill patients with Pseudomonas aeruginosa, extended infusion reduced 14-day mortality from 31.6% to 12.2% (p=0.04) and shortened hospital stay from 38 to 21 days 3

Rationale: Beta-lactams like piperacillin exhibit time-dependent killing. Maximizing the percentage of time that free drug concentrations remain above the pathogen's MIC (ideally 100% fT>MIC) optimizes bacterial eradication 2, 5. Extended infusions achieve this more reliably than intermittent boluses, particularly against organisms with higher MICs 2, 3, 4.

Dosing Adjustments for Special Populations

Renal Impairment:

• CrCl >40 mL/min: No adjustment needed (3.375 g q6h)
• CrCl 20-40 mL/min: Reduce to 2.25 g q6h
• CrCl <20 mL/min: Reduce to 2.25 g q8h
• Hemodialysis: 2.25 g q12h plus 0.75 g after each dialysis session 1

Critically Ill Patients with Augmented Renal Clearance:

• Standard dosing may be inadequate in patients with eGFR ≥100 mL/min 6, 7
• Consider higher doses (18-22.5 g/day by continuous infusion) or therapeutic drug monitoring 7
• In one ICU study, 37% of patients receiving standard doses had subtherapeutic concentrations, predominantly those with normal-to-augmented renal clearance 6

Obesity:

• Standard dosing is generally adequate for mild-to-moderate infections 8
• For critically ill patients with obesity, use extended infusion (4-hour infusion every 8 hours) or continuous infusion with therapeutic drug monitoring 8
• Higher dosing is NOT routinely recommended but extended infusions increase probability of target attainment 8

Preparation and Compatibility

Thawing (for GALAXY containers):

• Thaw at room temperature (20-25°C) or under refrigeration (2-8°C)
• Do NOT force thaw with water baths or microwave 1
• Check for leaks by squeezing container; discard if leaks detected 1

Compatibility:

• Compatible with Lactated Ringer's via Y-site when ZOSYN contains EDTA 1
• Administer separately from aminoglycosides (reconstitute, dilute, and infuse separately; Y-site co-administration possible under specific conditions) 1
• Do NOT add supplementary medications to the container 1

Clinical Pearls and Pitfalls

Common Pitfalls:

• Using 30-minute infusions in critically ill patients or those with Pseudomonas infections—this frequently results in subtherapeutic exposure 3, 6, 4
• Failing to adjust for augmented renal clearance in younger, critically ill patients without traditional renal impairment 6, 7
• Not recognizing that the 8:1 piperacillin:tazobactam ratio may be inadequate in patients with high eGFR, potentially leading to tazobactam underexposure against ESBL-producing organisms 7

Monitoring Considerations:

• Consider therapeutic drug monitoring in critically ill patients, those on renal replacement therapy, or with augmented renal clearance 5, 7
• Target trough concentrations >16 mg/L for efficacy against susceptible pathogens 6
• Monitor renal function closely—piperacillin/tazobactam is an independent risk factor for acute kidney injury in critically ill patients 1

Nosocomial Pneumonia Exception:

• For nosocomial pneumonia specifically, use 4.5 g every 6 hours (not 3.375 g) plus an aminoglycoside 1

2, 9, 5, 1, 3, 6, 4, 7